EchoIQ Limited (EIQ) was downgraded to a Hold Rating at Bell Potter

Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Imugene, and Cyclopharm Limited. According to TipRanks, Hester has an average return of 11.3% and a 47.22% success rate on recommended stocks.

EchoIQ Limited has an analyst consensus of Strong Buy, with a price target consensus of A$1.71.

Based on EchoIQ Limited’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$90.91 thousand and a GAAP net loss of A$8.66 million. In comparison, last year the company earned a revenue of A$101.41 thousand and had a GAAP net loss of A$6.22 million